Patents by Inventor Perry Francis Bartlett

Perry Francis Bartlett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9890358
    Abstract: The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: February 13, 2018
    Assignee: The University of Queensland
    Inventors: Tara Louise Walker, Perry Francis Bartlett
  • Patent number: 8790889
    Abstract: A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a ?3 adrenergic receptor agonist.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: July 29, 2014
    Assignee: The University of Queensland
    Inventors: Dhanisha Jhaveri, Perry Francis Bartlett
  • Publication number: 20130004984
    Abstract: A method of activating a latent neural precursor cell population, comprising: (1) providing a neural cell population derived from the hippocampus; (2) introducing the neural cell population to a neurosphere-forming culture medium; and (3) activating the latent precursor cell population by treatment with a ?3 adrenergic receptor agonist.
    Type: Application
    Filed: December 21, 2010
    Publication date: January 3, 2013
    Applicant: The University of Queensland
    Inventors: Dhanisha Jhaveri, Perry Francis Bartlett
  • Patent number: 8299027
    Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: October 30, 2012
    Assignee: The University of Queensland
    Inventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
  • Publication number: 20120195860
    Abstract: The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof.
    Type: Application
    Filed: April 10, 2008
    Publication date: August 2, 2012
    Inventors: Tara Louise Walker, Perry Francis Bartlett
  • Publication number: 20110172143
    Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins as well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.
    Type: Application
    Filed: September 17, 2010
    Publication date: July 14, 2011
    Applicant: University of Queensland, The
    Inventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
  • Patent number: 7919471
    Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: April 5, 2011
    Assignee: The University of Queensland
    Inventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar
  • Patent number: 7435586
    Abstract: The present invention relates generally to a method for the generation of a substantially homogeneous population of undifferentiated cells. More particularly, the present invention relates to the purification of a substantially homogeneous population of stem cells and their progenitor or precursor cells. Even more particularly, the present invention provides a population of neural stem cells (NSCs). The subject invention is particularly directed to NSCs and precursor cells with the capacity to differentiate into cells and cell lineages required for the development, maintenance or repair of the central nervous system in an animal such as a mammal. The present invention is further directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages, such as but not limited to neurons, oligodendrocytes, glia and astrocytes.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: October 14, 2008
    Assignee: The University of Queensland
    Inventors: Perry Francis Bartlett, Rodney Lee Rietze
  • Publication number: 20040235158
    Abstract: The present invention relates generally to a method for the generation of a substantially homogeneous population of undifferentiated cells. More particularly, the present invention relates to the purification of a substantially homogeneous population of stem cells and their progenitor or precursor cells. Even more particularly, the present invention provides a population of neural stem cells (NSCs). The subject invention is particularly directed to NSCs and precursor cells in the capacity to differentiate into cells and cell lineages required for the development, maintenance or repair of the central nervous system in an animal such as a mammal. The present invention is further directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages, such as but not limited to neurons, oligodendrocytes, glia and astrocytes.
    Type: Application
    Filed: June 29, 2004
    Publication date: November 25, 2004
    Inventors: Perry Francis Bartlett, Rodney Lee Rietze
  • Publication number: 20030162700
    Abstract: The present invention relates generally to a method of treatment and to agents useful for same. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic condition and even more particularly an encephalomyelopathic condition. The present invention further provides the use of leukemia inhibitory factor or derivatives, homologous or analogues thereof in the manufacture of a medicament for the treatment and/or prophylaxis of a nervous system disease, demyelinating disease and/or an inflammatory disease of either the central or peripheral nervous system such as but not limited to an encephalopathic and more particularly an encephalomyelopathic condition.
    Type: Application
    Filed: April 9, 2003
    Publication date: August 28, 2003
    Inventors: Kylie Ann-Maree Shipham, Tamara Ann Michelle Bucci, Helmut Butzkueven, Trevor John Kilpatrick, Perry Francis Bartlett
  • Publication number: 20020137188
    Abstract: The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonizing death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR.
    Type: Application
    Filed: March 30, 2001
    Publication date: September 26, 2002
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Perry Francis Bartlett, Elizabeth Jane Coulson, Katrina Fieldew, Manuel Baca, Trevor Kilpatrick, Cheema Surindar